Since combination therapy had no significant effect on MYCN mRNA levels assessed by qPCR comparing treated and untreated in neuroblastoma cells (Fig. S3b), we performed a cycloheximide chase experiment to assess the effect of combination therapy on MYCN protein half-life in MYCN-amplified Kelly cells (Fig. 3c). The gene discussed is MYCN; the disease is neuroblastoma.